论文部分内容阅读
我院从1998年10月～1999年8月应用凯西莱片(硫普罗宁)治疗病毒性肝炎70例并随机选择相同病种的70例作为对照组,以评价凯西莱的临床疗效,现将结果报告如下:1 资料与方法1.1 一般资料:140例均为住院患者,男92例,女48例,年龄5～67岁,平均28.7岁;急性病毒性肝炎74例,慢性病毒性肝炎轻型20例,中型46例.诊断标准按1995年5月北京第5次全国传染病寄生虫病会议修订的《病毒性肝炎防治方案》统计.随机设治疗组70例(急性肝炎37例,慢性肝炎33例)和对照组70例(急性肝炎37例,慢性肝炎33例).两组病例的年龄、性别、临床类型、症状、体征及肝功能改变情况基本相同,具有可比性.
Our hospital from October 1998 ~ August 1999 application of cassiratlor tablets (tiopronin) in the treatment of viral hepatitis in 70 patients and 70 patients were randomly selected the same type of disease as a control group to evaluate the clinical efficacy of cassiter, The results are reported as follows: 1 Materials and Methods 1.1 General Information: 140 cases were hospitalized patients, 92 males and 48 females, aged 5 to 67 years, mean 28.7 years; 74 cases of acute viral hepatitis, chronic viral hepatitis 20 cases, and medium-sized 46 cases.According to the “Viral Hepatitis Prevention and Control Program” revised by the 5th National Infectious Diseases Parasitology Conference in Beijing in May 1995, 70 cases were randomly divided into treatment group (37 cases of acute hepatitis, chronic hepatitis 33 cases) and control group of 70 cases (37 cases of acute hepatitis and 33 cases of chronic hepatitis) .The age, gender, clinical type, symptoms, signs and changes of liver function in the two groups were basically the same and comparable.